{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Innoviva, Inc. Forms Death Cross, Signaling Potential Bearish Trend Ahead
Innoviva, Inc. has recently encountered a technical event known as a Death Cross, indicating a potential shift in market sentiment. Current indicators reflect a bearish outlook, with the stock underperforming the S&P 500 over the past year, raising concerns about its competitive position in the Pharmaceuticals & Biotechnology sector.
Is Innoviva, Inc. overvalued or undervalued?
As of October 17, 2025, Innoviva, Inc. is considered overvalued with a P/E ratio of 15, a low PEG ratio of 0.20, and has underperformed the S&P 500, suggesting it may not be a compelling investment compared to its peers.
Innoviva, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Market Landscape
Innoviva, Inc. has recently adjusted its valuation, with a P/E ratio of 15 and a Price to Book Value of 3.16. The company demonstrates strong operational efficiency, reflected in its EV to EBIT and EV to EBITDA ratios, alongside notable returns on capital and equity compared to its peers.
Is Innoviva, Inc. overvalued or undervalued?
As of October 17, 2025, Innoviva, Inc. is considered overvalued due to its lower P/E ratio of 15 compared to peers, despite strong growth potential indicated by a PEG ratio of 0.20, and its recent stock performance has lagged behind the S&P 500.
Is Innoviva, Inc. overvalued or undervalued?
As of October 17, 2025, Innoviva, Inc. is considered overvalued with a P/E ratio of 15 and other high valuation metrics, despite strong profitability indicators like a 28.07% ROCE and 20.43% ROE.
Innoviva, Inc. Stock Plummets to New 52-Week Low of $16.52
Innoviva, Inc. has reached a new 52-week low of USD 16.52, significantly down from its high of USD 22. The company, with a market cap of USD 1,944 million, shows a 9.1% gain over the past year, lower than the S&P 500's 13.39%. Innoviva has a P/E ratio of 15.00 and a low debt-to-equity ratio of 0.03, indicating conservative leverage. The return on equity is 16.58%, but the company does not offer dividends.
Innoviva, Inc. Hits 52-Week Low at USD 16.59 Amid Market Volatility
Innoviva, Inc. has reached a new 52-week low of USD 16.59, contrasting with its 1-year performance of 4.58%. With a market cap of USD 1,944 million, a P/E ratio of 15.00, and a low debt-to-equity ratio of 0.03, the company emphasizes reinvestment over dividends.
Innoviva, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Fluctuations
Innoviva, Inc., a small-cap pharmaceutical company, has experienced stock fluctuations, with a recent closing price of $19.19. The stock's performance has varied, showing a year-to-date return of 9.74%, while trailing behind the S&P 500. Recent evaluations highlight the company's position amid market challenges.
Is Innoviva, Inc. technically bullish or bearish?
As of September 19, 2025, Innoviva, Inc. shows a bearish trend with key indicators signaling caution, as it has underperformed against the S&P 500 recently.
Is Innoviva, Inc. technically bullish or bearish?
As of September 19, 2025, Innoviva, Inc. shows a bearish technical trend with key indicators suggesting a shift from mildly bullish to sideways, underperforming the S&P 500 over the past week, month, and year.
Is Innoviva, Inc. technically bullish or bearish?
As of August 11, 2025, Innoviva, Inc. shows a mildly bullish technical trend with positive MACD and Bollinger Band signals, despite some bearish indicators, having outperformed the S&P 500 in the past week but underperformed over longer periods.
Is Innoviva, Inc. overvalued or undervalued?
As of August 6, 2025, Innoviva, Inc. is considered overvalued with a valuation grade of expensive, reflected in its P/E ratio of 15 and lower attractiveness compared to peers, despite a year-to-date stock return of 14.64% that slightly outperformed the S&P 500.
Is Innoviva, Inc. overvalued or undervalued?
As of May 7, 2025, Innoviva, Inc. is considered overvalued with a risky valuation grade, reflected by a P/E ratio of 15, an EV to EBITDA of 9.21, and a PEG ratio of 0.20, indicating that its earnings stability does not justify its price, especially compared to peers and despite a strong past year return of 30.94% that underperformed the S&P 500's 10.26%.
Is Innoviva, Inc. technically bullish or bearish?
As of June 10, 2025, Innoviva, Inc. shows a strong bullish trend supported by positive MACD and moving averages, despite some mixed signals from KST and Dow Theory.
Who are in the management team of Innoviva, Inc.?
As of March 2022, the management team of Innoviva, Inc. includes Dr. Odysseas Kostas (Independent Chairman), and Independent Directors Mr. George Bickerstaff, Mr. Mark DiPaolo, Mr. Jules Haimovitz, and Dr. Sarah Schlesinger. They guide the company's strategic direction.
What does Innoviva, Inc. do?
Innoviva, Inc. develops and manages bio-pharmaceuticals, primarily focusing on respiratory treatments. As of March 2025, it reported net sales of $92 million and a net loss of $47 million, with a market cap of approximately $2.03 billion.
How big is Innoviva, Inc.?
As of Jun 18, Innoviva, Inc. has a market capitalization of $2.03 billion, with net sales of $383.64 million and a net profit of -$59.73 million over the last four quarters. Shareholder's funds are $691.16 million, and total assets amount to $1.34 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
